3 ms·
"The drug, called aducanumab, appears to have met or exceeded Wall Street expectations in terms of how much the highest dose slowed cognitive decline. However,
by omgitstom 12y ago
"The drug, called aducanumab, appears to have met or exceeded Wall Street expectations in terms of how much the highest dose slowed cognitive decline. However, there was a high incidence of a particular side effect that might make it difficult to use the highest dose."
There is so much that scares me about this statement.
- randyrand 12y agoPersonally I think it's promising enough that there is nothing bad about the increased R&D money they'll have due to higher stock price. What do you think?